$15.02
1.14% today
Nasdaq, Sep 24, 08:47 pm CET
ISIN
US87164F1057
Symbol
SNDX

Syndax Pharmaceuticals Inc Stock price

$14.85
-0.81 5.17% 1M
+1.12 8.16% 6M
+1.63 12.33% YTD
-3.08 17.18% 1Y
-8.09 35.27% 3Y
+1.15 8.39% 5Y
+2.84 23.65% 10Y
+2.84 23.65% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.04 0.27%
ISIN
US87164F1057
Symbol
SNDX
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.2b
Net debt
positive
Cash
$468.7m
Shares outstanding
86.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.4 | 7.3
EV/Sales
14.8 | 6.6
EV/FCF
negative
P/B
8.1
Financial Health
Equity Ratio
39.8%
Return on Equity
-110.6%
ROCE
-70.2%
ROIC
-
Debt/Equity
2.2
Financials (TTM | estimate)
Revenue
$78.2m | $175.8m
EBITDA
$-339.1m | $-316.8m
EBIT
$-339.1m | $-277.6m
Net Income
$-335.0m | $-282.0m
Free Cash Flow
$-302.7m
Growth (TTM | estimate)
Revenue
2,133.7% | 642.4%
EBITDA
-17.7% | 6.7%
EBIT
-17.7% | 18.3%
Net Income
-26.9% | 11.5%
Free Cash Flow
-25.5%
Margin (TTM | estimate)
Gross
80.2%
EBITDA
-433.7% | -180.2%
EBIT
-433.7%
Net
-428.5% | -160.4%
Free Cash Flow
-387.1%
More
EPS
$-3.9
FCF per Share
$-3.5
Short interest
27.4%
Employees
270
Rev per Employee
$90.0k
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
95%
Hold
5%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
78 78
2,134% 2,134%
100%
- Direct Costs 2.99 2.99
-
4%
63 63
-
80%
- Selling and Administrative Expenses 154 154
67% 67%
197%
- Research and Development Expense 260 260
31% 31%
333%
-339 -339
18% 18%
-434%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -339 -339
18% 18%
-434%
Net Profit -335 -335
27% 27%
-428%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
5 days ago
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.
Neutral
GlobeNewsWire
5 days ago
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to include revumenib as a category 2A recommendation for ...
Positive
Seeking Alpha
14 days ago
FDA approval of revumenib for r/r KMT2Ar AML patients drives strong revenue growth for Syndax Pharmaceuticals, with Q2 2025 sales up 43% quarter-over-quarter. Upcoming FDA Priority Review decision for sNDA in r/r mNPM1 AML offers a significant near-term catalyst, with a PDUFA date set for October 25, 2025. Expansion into metastatic MSS colorectal cancer represents a major pipeline opportunity, ...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today